Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Healthy long term growth as Operating profit has grown by an annual rate 28.74%
3
Negative results in Jun 25
4
With ROE of 8.27%, it has a very attractive valuation with a 1.08 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 76,316 Million (Small Cap)
13.00
NA
0.02%
0.10
8.36%
1.17
Revenue and Profits:
Net Sales:
19,321 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,344 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.93%
0%
-19.93%
6 Months
-15.51%
0%
-15.51%
1 Year
-6.04%
0%
-6.04%
2 Years
10.64%
0%
10.64%
3 Years
59.95%
0%
59.95%
4 Years
101.76%
0%
101.76%
5 Years
0%
0%
0.0%
ASKA Pharmaceutical Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.07%
EBIT Growth (5y)
28.74%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.17
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.88
Tax Ratio
17.62%
Dividend Payout Ratio
30.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.64%
ROE (avg)
11.79%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.08
EV to EBIT
13.13
EV to EBITDA
9.24
EV to Capital Employed
1.08
EV to Sales
1.09
PEG Ratio
NA
Dividend Yield
0.02%
ROCE (Latest)
8.20%
ROE (Latest)
8.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
19,321.00
16,352.00
18.16%
Operating Profit (PBDIT) excl Other Income
2,063.00
2,257.00
-8.60%
Interest
51.00
11.00
363.64%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,344.00
1,273.00
5.58%
Operating Profit Margin (Excl OI)
76.50%
107.50%
-3.10%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 18.16% vs 2.05% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 5.58% vs -10.85% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
64,139.00
62,843.00
2.06%
Operating Profit (PBDIT) excl Other Income
7,580.00
9,163.00
-17.28%
Interest
51.00
40.00
27.50%
Exceptional Items
-300.00
0.00
Consolidate Net Profit
5,101.00
7,545.00
-32.39%
Operating Profit Margin (Excl OI)
83.10%
103.40%
-2.03%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 2.06% vs 3.94% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -32.39% vs 78.03% in Mar 2024
About ASKA Pharmaceutical Holdings Co., Ltd. 
ASKA Pharmaceutical Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






